EU group wants new restrictions on dual medicines

<p>LONDON (Reuters) – European drugs regulators on Friday endorsed restricting a use of <span>tolperisone</span> and trimetazidine-containing medicines due to worries about a risk-benefit <span>balance</span>.</p>
<p> The <span>European Medicines Agency</span> (<span>EMA</span>) pronounced doctors should no longer allot <span>trimetazidine</span>, a <span>generic drug</span>, for a diagnosis of patients with tinnitus, vertigo or disturbances in vision, and in patients with <span>angina pectoris</span> they should shorten a use to usually a second-line or appendage therapy.</p>
<p> Patients holding trimetazidine should plead alternatives with their doctor, it said.</p>
<p> EMA pronounced a call for limitation on use of tolperisone, a general flesh relaxant drug used to provide spasticity and flesh spasms, was due to concerns...